Top

Published in:

01-12-2017 | Brief Research Article

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

Authors: J. Remon, D. Isla, P. Garrido, J. de Castro, M. Majem, N. Viñolas, A. Artal, E. Carcereny, M. R. García-Campelo, P. Lianes, M. Provencio, O. Juan, P. Diz, R. Blanco, R. Lopez-Castro, I. Maestu, C. Vadell, E. Felip

Published in: Clinical and Translational Oncology | Issue 12/2017

Abstract

Background

The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer.

Methods

WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis.

Results

From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women.

Conclusion

Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.

Hashim D, Boffetta P, La Vecchia C, Rota M, Bertuccio P, Malvezzi M, et al. The global decrease in cancer mortality: trends and disparities. Ann Oncol. 2016;27:926–33. doi:10.1093/annonc/mdw027.CrossRefPubMed

Malavezzi M, Cariolu G, Bertuccio P, Boffetta P, levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol 2017;0:1–7. doi:10.1093/annonc/mdx033.

Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48:889–902. doi:10.1183/13993003.00359-2016.CrossRefPubMed

Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15:415–53. doi:10.1016/j.jmoldx.2013.03.001.CrossRefPubMed

Barlesi F, Mazieres J, Merlio J-P, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387:1415–26. doi:10.1016/S0140-6736(16)00004-0.CrossRefPubMed

Paik PK, Drilon A, Fan P-D, Yu H, Rekhtman N, Ginsberg MS, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5:842–9. doi:10.1158/2159-8290.CD-14-1467.CrossRefPubMedPubMedCentral

Shaw AT, Ou S-HI, Bang Y-J, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963–71. doi:10.1056/NEJMoa1406766.CrossRefPubMedPubMedCentral

Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5:2892–911.PubMedPubMedCentral

Reguart N, Remon J. Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine-kinase inhibitors. Future Oncol. 2015;. doi:10.2217/fon.15.15.

10.

Lee CK, Wu Y-L, Ding PN, Lord SJ, Inoue A, Zhou C, et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. J Clin Oncol. 2015;33:1958–65. doi:10.1200/JCO.2014.58.1736.CrossRefPubMed

11.

Isla D, Felip E, Viñolas N, Provencio M, Majem M, Artal A, et al. Lung cancer in women with a family history of cancer: the Spanish female-specific database WORLD07. Anticancer Res. 2016;36:6647–53. doi:10.21873/anticanres.11273.CrossRefPubMed

12.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.CrossRefPubMed

13.

Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. J Clin Oncol. 2011;29:7519.CrossRef

14.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46. doi:10.1016/S1470-2045(11)70393-X.CrossRefPubMed

15.

Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998–2006. doi:10.1001/jama.2014.3741.CrossRefPubMedPubMedCentral

16.

Esteban E, Majem M, Martinez Aguillo M, Martinez Banaclocha N, Dómine M, Gómez Aldaravi L, et al. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: the Spanish REASON study. Cancer Epidemiol. 2015;39:291–7. doi:10.1016/j.canep.2015.02.003.CrossRefPubMed

17.

Fukuhara T, Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer. 2015;88:181–6. doi:10.1016/j.lungcan.2015.02.004.CrossRefPubMed

18.

Smit EF, Wu Y-L, Gervais R, Zhou C, Felip E, Feng J, et al. A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). Lung Cancer. 2016;99:94–101. doi:10.1016/j.lungcan.2016.06.019.CrossRefPubMed

19.

Yang JJ, Zhou Q, Yan HH, et al. A randomized controlled trial of erlotinib versus gefitinib in advanced non-small cell lung cancer harboring EGFR mutations (CTONG0901). J Thorac Oncol. 2015;10:321 (Abstract MINI 1613).

20.

Park K, Tan E-H, O’Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577–89. doi:10.1016/S1470-2045(16)30033-X.CrossRefPubMed

21.

Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017;28(2):270–7. doi:10.1093/annonc/mdw611.CrossRefPubMedPubMedCentral

22.

Leduc C, Blons H, Besse B, Merlio J-P, Debieuvre D, Lemoine A, monnet I et al. Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Ann Oncol. 2016;27(suppl_6):1202O. doi:10.1093/annonc/mdw383.02.

23.

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–67. doi:10.1056/NEJMoa0904554.CrossRefPubMed

24.

Miyauchi E, Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, et al. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Jpn J Clin Oncol. 2015;45:670–6. doi:10.1093/jjco/hyv054.CrossRefPubMed

Title: Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database
Authors: J. Remon
D. Isla
P. Garrido
J. de Castro
M. Majem
N. Viñolas
A. Artal
E. Carcereny
M. R. García-Campelo
P. Lianes
M. Provencio
O. Juan
P. Diz
R. Blanco
R. Lopez-Castro
I. Maestu
C. Vadell
E. Felip
Publication date: 01-12-2017
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 12/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1700-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2017

Annual hazard rate of relapse of stage II and III colorectal cancer after primary therapy

Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia

Overexpression of dishevelled 2 is involved in tumor metastasis and is associated with poor prognosis in hepatocellular carcinoma

Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique

Haemoglobin monitoring in endometrial cancer patients undergoing radiotherapy

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

Keynote webinar | Spotlight on antibody–drug conjugates in cancer